Key terms
About KOD
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KOD news
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
9:03am ET
Capital One reveals top six biotech picks for 2024
Dec 11
6:35am ET
Cautious Sell Rating on Kodiak Sciences Amid Clinical and Regulatory Uncertainties
Dec 11
6:27am ET
Kodiak Sciences reinstated with a Sell at Goldman Sachs
No recent news articles are available for KOD
No recent press releases are available for KOD
KOD Financials
Key terms
Ad Feedback
KOD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KOD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range